钠-葡萄糖协同转运蛋白2抑制剂的心血管获益机制探讨

刘智杰; 边宁; 潘贇; 陈冬冬

doi:10.13201/j.issn.1001-1439.2021.12.002

钠-葡萄糖协同转运蛋白2抑制剂的心血管获益机制探讨

- 暨南大学附属第一医院心内科(广州, 510630)

详细信息

通讯作者: 陈冬冬,E-mail:449244049@qq.com

中图分类号: R54

收稿日期: 2021-05-19

修回日期: 2021-06-26

The mechanisms of sodium-glucose cotransporter 2 inhibitor in bringing cardiovascular benefits

- Department of Cardiology, The First Affiliated Hospital of Ji'nan University, Guangzhou, 510630, China

More Information

Corresponding author: CHEN Dongdong, E-mail: 449244049@qq.com

Received Date: 19 May 2021

Revised Date: 26 June 2021

摘要

摘要: 心血管疾病(CVD)和糖尿病在全世界范围内影响着人类的生命和健康,当两者共存时更是形成相互促进的恶性循环,进一步增加风险和病死率。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一类新型口服降糖药,除了能降低血糖之外,还显示出了明显的心血管获益作用,然而具体的机制目前尚未明确。本文将查阅和学习近期相关文献,总结SGLT2抑制剂在心血管方面的研究进展,以探讨其对心血管获益的可能机制,旨在能够为SGLT2抑制剂在CVD中的进一步应用提供依据,以改善CVD患者的临床结局。
- 钠-葡萄糖协同转运蛋白2抑制剂 /
- 心血管疾病 /
- 糖尿病 /
- 获益机制
Abstract: Cardiovascular diseases(CVD) and diabetes mellitus pose a threat to human life and health worldwide. A vicious circle of mutual promotion will take shape to increase risk and mortality further when CVD is complicated with diabetes mellitus. As a new oral hypoglycemic agent, sodium-glucose cotransporter 2(SGLT2) inhibitor has shown significant cardiovascular benefits in addition to lowering blood glucose. However, the specific mechanism has not been elucidated presently. In order to provide a basis for the further application of SGLT2 inhibitor in CVD and to improve the clinical prognosis of such patients, this article would consult and study latest pertinent literature and summarize the recent advance of SGLT2 inhibitor in cardiovascular terms and explore the potential mechanisms of its cardiovascular benefits.
- sodium-glucose cotransporter 2 inhibitor /
- cardiovascular disease /
- diabetes mellitus /
- benefit mechanism

HTML全文

参考文献(38)

[1]	Timmis A,Townsend N,Gale CP,et al.European society of cardiology:cardiovascular disease statistics 2019[J].Eur Heart J,2020,41(1):12-85.
[2]	Dong W,Wan E,Bedford LE,et al.Prediction models for the risk of cardiovascular diseases in Chinese patients with type 2diabetes mellitus:a systematic review[J].Public Health,2020,186:144-156.
[3]	Urquhart S,Willis S.Long-acting GLP-1receptor agonists:Findings and implications of cardiovascular outcomes trials[J].JAAPA,2020,33(S8Suppl 1):19-30.
[4]	Brown E,Wilding JP,Alam U,et al.The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection[J].Ann Med,2020:1-32.
[5]	Sano M,Goto S.Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects[J].Circulation,2019,139(17):1985-1987.
[6]	Herat LY,Magno AL,Rudnicka C,et al.SGLT2 inhibitor-induced sympathoinhibition:a novel mechanism for cardiorenal protection[J].JACC Basic Transl Sci,2020,5(2):169-179.
[7]	Lonn EM,Rambihar S,Gao P,et al.Heart rate is associated with increased risk of major cardiovascular events,cardiovascular and all-cause death in patients with stable chronic cardiovascular disease:an analysis of ONTARGET/TRANSCEND[J].Clin Res Cardiol,2014,103(2):149-159.
[8]	Sano M,Chen S,Imazeki H,et al.Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin:Subanalysis of placebocontrolled,double-blind clinical trials[J].J Diabetes Investig,2018,9(3):638-641.
[9]	Lee SG,Lee SJ,Lee JJ,et al.Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2(SGLT-2)inhibitor in a normoglycemic rabbit model[J].Korean Circ J,2020,50(5):443-457.
[10]	Verma A,Patel AB,Waikar SS.SGLT2 inhibitor:not a traditional diuretic for heart failure[J].Cell Metab,2020,32(1):13-14.
[11]	Ray EC.Evolving understanding of cardiovascular protection by SGLT2 inhibitors:focus on renal protection,myocardial effects,uric acid,and magnesium balance[J].Curr Opin Pharmacol,2020,54:11-17.
[12]	Takaori K,Nakamura J,Yamamoto S,et al.Severity and frequency of proximal tubule injury determines renal prognosis[J].J Am Soc Nephrol,2016,27(8):2393-2406.
[13]	Ferrara D,Montecucco F,Dallegri F,et al.Impact of different ectopic fat depots on cardiovascular and metabolic diseases[J].J Cell Physiol,2019,234(12):21630-21641.
[14]	Sato T,Aizawa Y,Yuasa S,et al.The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices:An ad-hoc analysis of the previous randomized clinical trial[J].J Atheroscler Thromb,2020,27(12):1348-1358.
[15]	Wu P,Wen W,Li J,et al.Systematic review and metaanalysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2diabetes[J].Horm Metab Res,2019,51(8):487-494.
[16]	Shin SH,Claggett B,Pfeffer MA,et al.Hyperglycaemia,ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2diabetes and a recent acute coronary syndrome[J].Eur J Heart Fail,2020,22(7):1133-1143.
[17]	Szekeres Z,Toth K,Szabados E.The effects of SGLT2 inhibitors on lipid metabolism[J].Metabolites,2021,11(2).
[18]	Zhao Y,Xu L,Tian D,et al.Effects of sodium-glucose co-transporter 2(SGLT2)inhibitors on serum uric acid level:A meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2018,20(2):458-462.
[19]	Chen L,Jin C,Chen L,et al.Value of microalbuminuria in the diagnosis of heart failure with preserved ejection fraction[J].Herz,2021,46(Suppl 2):215-221.
[20]	Cherney D,Lund SS,Perkins BA,et al.The effect of sodium glucose cotransporter 2inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes[J].Diabetologia,2016,59(9):1860-1870.
[21]	李雪博,李昌海,王孝锋,等.心外膜脂肪组织、肥胖与心房颤动的研究进展[J].临床心血管病杂志,2020,36(2):193-195.
[22]	Gast KB,Tjeerdema N,Stijnen T,et al.Insulin resistance and risk of incident cardiovascular events in adults without diabetes:meta-analysis[J].PLoS One,2012,7(12):e52036.
[23]	Katakami N.Mechanism of development of atherosclerosis and cardiovascular disease in diabetes mellitus[J].J Atheroscler Thromb,2018,25(1):27-39.
[24]	El-Daly M,Pulakazhi Venu VK,Saifeddine M,et al.Hyperglycaemic impairment of PAR2-mediated vasodilation:Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2and minimizing oxidative stress[J].Vascul Pharmacol,2018,109:56-71.
[25]	刘圣,周骏腾,张庆.动脉僵硬度无创评估及其在心力衰竭中的应用[J].心血管病学进展,2020,41(11):1160-1163.
[26]	Lee DM,Battson ML,Jarrell DK,et al.SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2diabetic mice[J].Cardiovasc Diabetol,2018,17(1):62.
[27]	Georgianos PI,Agarwal R.Ambulatory blood pressure reduction with SGLT-2inhibitors:dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide[J].Diabetes Care,2019,42(4):693-700.
[28]	Singh JS,Fathi A,Vickneson K,et al.Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus(REFORM)trial rationale and design[J].Cardiovasc Diabetol,2016,15:97.
[29]	Li C,Zhang J,Xue M,et al.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J].Cardiovasc Diabetol,2019,18(1):15.
[30]	Karwi QG,Biswas D,Pulinilkunnil T,et al.Myocardial Ketones Metabolism in Heart Failure[J].J Card Fail,2020,26(11):998-1005.
[31]	Joshi SS,Singh T,Newby DE,et al.Sodium-glucose co-transporter 2inhibitor therapy:mechanisms of action in heart failure[J].Heart,2021,107(13):1032-1038.
[32]	Uthman L,Baartscheer A,Bleijlevens B,et al.Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts:inhibition of Na/H exchanger,lowering of cytosolic Na and vasodilation[J].Diabetologia,2018,61(3):722-726.
[33]	Neri M,Riezzo I,Pascale N,et al.Ischemia/reperfusion injury following acute myocardial infarction:Acritical issue for clinicians and forensic pathologists[J].Mediators Inflamm,2017:7018393.
[34]	Andreadou I,Bell RM,Bøtker HE,et al.SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models[J].Biochim Biophys Acta Mol Basis Dis,2020,1866(7):165770.
[35]	Packer M.Molecular,cellular,and clinical evidence that sodium-glucose cotransporter 2inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure[J].J Am Heart Assoc,2020,9(16):e016270.
[36]	Osataphan S,Macchi C,Singhal G,et al.SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and-independent mechanisms[J].JCI Insight,2019,4(5).
[37]	Shah SJ,Lam C,Svedlund S,et al.Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction:PROMIS-HF-pEF[J].Eur Heart J,2018,39(37):3439-3450.
[38]	Adingupu DD,Göpel SO,Grönros J,et al.SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob-/-mice[J].Cardiovasc Diabetol,2019,18(1):16.